The effect of GLP-1RAs on cardiovascular disease and cardio-metabolic risk factors in patients with obesity and/or type 2 diabetes

27 August 2023 (12:55 - 13:13)

Organised by:

About the speaker

Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)

5 More presentations in this session

Presentation thumbnail

Welcome and introductions: cardiovascular risk in people with type 2 diabetes and/or obesity

Professor N. Marx (Aachen, DE)

Presentation thumbnail

GLP-1RAs: what does the future hold?

Doctor T. Vilsboll (Copenhagen, DK)

Presentation thumbnail

A focus on the practical: how can cardiologists best utilise GLP-1RAs in the clinic?

Professor N. Marx (Aachen, DE)

Presentation thumbnail

Panel discussion and Q&A

Presentation thumbnail

Closing

Professor N. Marx (Aachen, DE)

Access the full session

Session thumbnail

A multidisciplinary approach to type 2 diabetes, obesity, and cardiovascular diseases: current evidence and a glimpse into the future

The Event

Event poster

ESC Congress 2023

27 August 2023 12:55 CET

You may be interested in

Webinar

GLP-1 RAs and HFpEF : what do we know from large RCTs about GLP-1 RAs and their effects on HFpEF?

24 November 2025

Congress Presentation

Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes

1 September 2025

Congress Presentation

Effect of glucagon-like peptide-1 receptor agonists on blood pressure: a systematic review and meta-analysis

4 April 2025

Congress Session

GLP-1 RAs: more than just glucose-lowering agents

28 August 2022

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources